Friedman Deborah I, Quiros Peter A, Subramanian Prem S, Mejico Luis J, Gao Shan, McDermott Michael, Wall Michael
Department of Ophthalmology, University of California Los Angeles, Los Angeles, CA, USA.
Departments of Neurology & Neurotherapeutics and Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Headache. 2017 Sep;57(8):1195-1205. doi: 10.1111/head.13153. Epub 2017 Jul 28.
To characterize the phenotype, headache-related disability, medical co-morbidities, use of symptomatic headache medications, and headache response to study interventions in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT).
Patients with untreated IIH and mild vision loss enrolled in the IIHTT and randomized to acetazolamide (ACZ) and weight loss or placebo (PLB) and weight loss had prospective assessment of headache disability using the Headache Impact Test-6 (HIT-6) questionnaire. Subjects with headache at the baseline visit were assigned a headache phenotype using the International Classification for Headache Disorders version 3 beta (ICHD-3b). Medication overuse was determined using the participants' reported medication use for the preceding month and ICHD-3b thresholds for diagnosing medication overuse headache. We investigated relationships between headache disability and various other clinical characteristics at baseline and at 6 months.
Headache was present in 139 (84%) of the 165 enrollees at baseline. The most common headache phenotypes were migraine (52%), tension-type headache (22%), probable migraine (16%), and probable tension-type headache (4%). Fifty-one (37%) participants overused symptomatic medications at baseline, most frequently simple analgesics. A similar amount of improvement in the adjusted mean (± standard error) HIT-6 score occurred in the ACZ (-9.56 ± 1.05) and PLB groups (-9.11 ± 1.14) at 6 months (group difference -0.45, 95% CI -3.50 to 2.60, P = .77). Headache disability did not correlate with any of the studies, variables of interest, which included: the lumbar puncture opening pressure at baseline or at 6 months, body mass index, the amount of weight lost, papilledema grade, perimetric mean deviation, or the use of hormonal contraception. Headache disability was significantly associated with patient-reported quality of life in the physical, mental, and visual domains.
Headache was common, of varied character, disabling, and associated with poorer quality of life in our cohort of patients with mild visual impairment. The lack of correlation between headache disability and cerebrospinal fluid (CSF) pressure at baseline and at the end of the randomized phase of the study implies that headache in IIH may be related to factors other than intracranial hypertension, and that specific headache treatment is needed in addition to therapies directed at lowering CSF pressure.
在特发性颅内高压治疗试验(IIHTT)中,对表型、头痛相关残疾、合并症、症状性头痛药物的使用以及研究干预措施的头痛反应进行特征描述。
纳入IIHTT中未经治疗的IIH且有轻度视力丧失的患者,随机分为乙酰唑胺(ACZ)联合减重组或安慰剂(PLB)联合减重组,使用头痛影响测试-6(HIT-6)问卷对头痛残疾进行前瞻性评估。在基线访视时头痛的受试者,根据国际头痛疾病分类第3版beta版(ICHD-3b)确定头痛表型。根据参与者报告的前一个月药物使用情况和ICHD-3b中诊断药物过量使用性头痛的阈值来确定药物过量使用情况。我们研究了基线和6个月时头痛残疾与其他各种临床特征之间的关系。
165名受试者中,139名(84%)在基线时有头痛症状。最常见的头痛表型为偏头痛(52%)、紧张型头痛(22%)、可能的偏头痛(16%)和可能的紧张型头痛(4%)。51名(37%)参与者在基线时过量使用症状性药物,最常见的是单纯镇痛药。6个月时,ACZ组(-9.56±1.05)和PLB组(-9.11±1.14)的调整后平均(±标准误)HIT-6评分改善程度相似(组间差异-0.45,95%CI -3.50至2.60,P = 0.77)。头痛残疾与任何研究感兴趣的变量均无相关性,这些变量包括:基线或6个月时的腰穿开放压、体重指数、减重的量、视乳头水肿分级、视野平均偏差或激素避孕的使用。头痛残疾与患者报告的身体、心理和视觉领域的生活质量显著相关。
在我们的轻度视力损害患者队列中,头痛很常见,性质多样,会导致残疾,并与较差的生活质量相关。在研究的随机阶段,基线和结束时头痛残疾与脑脊液(CSF)压力之间缺乏相关性,这意味着IIH中的头痛可能与颅内高压以外的因素有关,除了针对降低CSF压力的治疗外,还需要特定的头痛治疗。